Lung Cancer
July 2015
This bulletin covers aspects of lung cancer and should be of interest to multidisciplinary teams
working in this area.
Sections can include:
 Combined Modality Therapies
 Drug Therapy
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
 Tobacco & Smoking
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
General
Ettinger DS, Wood DE, Akerley W, et al. (2015). Non-Small Cell Lung Cancer,
Version 6.2015. Journal of the National Comprehensive Cancer Network 13,5:515524.
Combined Modality Therapies
Bharadwaj SC, Vallieres E, Wilshire CL, et al. (2015). Higher Versus Standard
Preoperative Radiation in the Trimodality Treatment of Stage IIIa Lung Cancer.
Annals of Thoracic Surgery 100,1:207-214.
Chang JY, Senan S, Paul MA, et al. (2015). Stereotactic ablative radiotherapy
versus lobectomy for operable stage I non-small-cell lung cancer: a pooled
analysis of two randomised trials. Lancet Oncology 16,6:630-637.
Hendriks LE, Schoenmaekers J, Zindler JD, et al. (2015). Safety of cranial
radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung
cancer patients: A systematic review. Cancer treatment reviews 41,7:634-645.
Komaki R, Allen PK, Wei X, et al. (2015). Adding Erlotinib to Chemoradiation
Improves Overall Survival but Not Progression-Free Survival in Stage III NonSmall Cell Lung Cancer. International journal of radiation oncology, biology, physics
92,2:317-324.
Moro-Sibilot D, Audigier-Valette C, Merle P, et al. (2015). Non-small cell lung cancer
recurrence following surgery and perioperative chemotherapy: Comparison of
two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results
study). Lung Cancer 89,2:139-145.
Strom HH, Bremnes RM, Sundstrom SH, et al. (2015). How Do Elderly Poor
Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally
Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a
Clinical Phase III Trial. Clinical Lung Cancer 16,3:183-192.
Drug & Targeted Therapy
Adam V, Dooms C and Vansteenkiste J. (2015). Lung cancer at the intensive care
unit: The era of targeted therapy. Lung Cancer 89,2:218-221.
Blumenschein GR Jr, Smit EF, Planchard D, et al. (2015). A randomized phase II
study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with
docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)+.
Annals of Oncology 26,5:894-901.
Brahmer J, Reckamp KL, Baas P, et al. (2015). Nivolumab versus Docetaxel in
Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of
Medicine 373,2:123-135.
2
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Camerini A, Puccetti C, Donati S, et al. (2015). Metronomic oral vinorelbine as firstline treatment in elderly patients with advanced non-small cell lung cancer:
results of a phase II trial (MOVE trial). BMC Cancer 15,359.
Ellis PM, Coakley N, Feld R, et al. (2015). Use of the epidermal growth factor
receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the
treatment of non-small-cell lung cancer: a systematic review. Current Oncology
22,3:e183-215.
Galetta D, Cinieri S, Pisconti S, et al. (2015). Cisplatin/Pemetrexed Followed by
Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed
by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The
GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized
Trial. Clinical Lung Cancer 16,4:262-273.
Garon EB, Rizvi NA, Hui R, et al. (2015). Pembrolizumab for the treatment of nonsmall-cell lung cancer. New England Journal of Medicine 372,21:2018-2028.
Genestreti G, Di Battista M, Cavallo G, et al. (2015). Maintenance therapy in nonsmall cell lung cancer. Expert Review of Anticancer Therapy 15,7:839-846.
Gerber DE, Oxnard GR and Govindan R. (2015). ALCHEMIST: Bringing genomic
discovery and targeted therapies to early-stage lung cancer. Clinical
Pharmacology & Therapeutics 97,5:447-450.
Greenhalgh J, Bagust A, Boland A, et al. (2015). Erlotinib and gefitinib for treating
non-small cell lung cancer that has progressed following prior chemotherapy
(review of NICE technology appraisals 162 and 175): a systematic review and
economic evaluation. Health technology assessment (Winchester, England) 19,47:1134.
Hong S, Tan M, Wang S, et al. (2015). Efficacy and safety of angiogenesis
inhibitors in advanced non-small cell lung cancer: a systematic review and metaanalysis. Journal of Cancer Research & Clinical Oncology 141,5:909-921.
Hooper CE, Lyburn ID, Searle J, et al. (2015). The South West Area Mesothelioma
and Pemetrexed trial: a multicentre prospective observational study evaluating
novel markers of chemotherapy response and prognostication. British journal of
cancer 112,7:1175-1182.
Janne PA, Yang JC, Kim DW, et al. (2015). AZD9291 in EGFR inhibitor-resistant
non-small-cell lung cancer. New England Journal of Medicine 372,18:1689-1699.
Krug LM, Kindler HL, Calvert H, et al. (2015). Vorinostat in patients with advanced
malignant pleural mesothelioma who have progressed on previous
chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebocontrolled trial. Lancet Oncology 16,4:447-456.
Lal R, Hillerdal GN, Shah RN, et al. (2015). Feasibility of home delivery of
pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
Lung Cancer 89,2:154-160.
Lara PN Jr, Moon J, Redman MW, et al. (2015). Relevance of platinum-sensitivity
status in relapsed/refractory extensive-stage small-cell lung cancer in the
modern era: a patient-level analysis of southwest oncology group trials. Journal
3
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
of Thoracic Oncology: Official Publication of the International Association for the Study
of Lung Cancer 10,1:110-115.
Lee CK, Wu YL, Ding PN, et al. (2015). Impact of Specific Epidermal Growth Factor
Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After
Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFRMutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology 33,17:19581965.
Miyauchi E, Inoue A, Kobayashi K, et al. (2015). Efficacy of chemotherapy after firstline gefitinib therapy in EGFR mutation-positive advanced non-small cell lung
cancer-data from a randomized Phase III study comparing gefitinib with
carboplatin plus paclitaxel (NEJ002). Japanese journal of clinical oncology 45,7:670676.
Nishino K, Imamura F, Kumagai T, et al. (2015). A randomized phase II study of
bevacizumab in combination with docetaxel or S-1 in patients with nonsquamous non-small-cell lung cancer previously treated with platinum based
chemotherapy (HANSHIN Oncology Group 0110). Lung Cancer 89,2:146-153.
O'Brien ME, Gaafar R, Hasan B, et al. (2015). Maintenance pazopanib versus
placebo in Non-Small Cell Lung Cancer patients non-progressive after first line
chemotherapy: A double blind randomised phase III study of the lung cancer
group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). European journal
of cancer 51,12:1511-1528.
Pilkington G, Boland A, Brown T, et al. (2015). A systematic review of the clinical
effectiveness of first-line chemotherapy for adult patients with locally advanced
or metastatic non-small cell lung cancer. Thorax 70,4:359-367.
Pujol JL, Lavole A, Quoix E, et al. (2015). Randomized phase II-III study of
bevacizumab in combination with chemotherapy in previously untreated
extensive small-cell lung cancer: results from the IFCT-0802 trial+. Annals of
Oncology 26,5:908-914.
Ready NE, Pang HH, Gu L, et al. (2015). Chemotherapy With or Without
Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A
Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504
(Alliance). Journal of Clinical Oncology 33,15:1660-1665.
Sequist LV, Soria JC, Goldman JW, et al. (2015). Rociletinib in EGFR-mutated nonsmall-cell lung cancer. New England Journal of Medicine 372,18:1700-1709.
Sugawara S, Oizumi S, Minato K, et al. (2015). Randomized phase II study of
concurrent versus sequential alternating gefitinib and chemotherapy in
previously untreated non-small cell lung cancer with sensitive EGFR mutations:
NEJ005/TCOG0902. Annals of Oncology 26,5:888-894.
Thatcher N, Hirsch FR, Luft AV, et al. (2015). Necitumumab plus gemcitabine and
cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients
with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label,
randomised, controlled phase 3 trial. Lancet Oncology 16,7:763-774.
Thomas M, Fischer J, Andreas S, et al. (2015). Erlotinib and bevacizumab versus
cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall
4
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
cell lung cancer. European Respiratory Journal 46,1:219-229.
Timmers L, Boons CC, Moes-Ten Hove J, et al. (2015). Adherence, exposure and
patients' experiences with the use of erlotinib in non-small cell lung cancer.
Journal of Cancer Research & Clinical Oncology 141,8:1481-1491.
Vale CL, Burdett S, Fisher DJ, et al. (2015). Should Tyrosine Kinase Inhibitors Be
Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type
EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.
Clinical Lung Cancer 16,3:173-182.e4.
Yang JC, Sequist LV, Geater SL, et al. (2015). Clinical activity of afatinib in patients
with advanced non-small-cell lung cancer harbouring uncommon EGFR
mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUXLung 6. Lancet Oncology 16,7:830-838.
Zhou F, Jiang T, Ma W, et al. (2015). The impact of clinical characteristics on
outcomes from maintenance therapy in non-small cell lung cancer: A systematic
review with meta-analysis. Lung Cancer 89,2:203-211.
Pathology, Staging, Polymorphisms & Biomarkers
Califano R, Abidin A, Tariq NU, et al. (2015). Beyond EGFR and ALK inhibition:
unravelling and exploiting novel genetic alterations in advanced non small-cell
lung cancer. Cancer treatment reviews 41,5:401-411.
Guldbrandt LM, Fenger-Gron M, Rasmussen TR, et al. (2015). The role of general
practice in routes to diagnosis of lung cancer in Denmark: a population-based
study of general practice involvement, diagnostic activity and diagnostic
intervals. BMC Health Services Research 15,21.
Kanodra NM, Silvestri GA and Tanner NT. (2015). Screening and early detection
efforts in lung cancer. Cancer 121,9:1347-1356.
Kauczor HU, Bonomo L, Gaga M, et al. (2015). ESR/ERS white paper on lung cancer
screening. European Respiratory Journal 46,1:28-39.
Lim C, Tsao MS, Le LW, et al. (2015). Biomarker testing and time to treatment
decision in patients with advanced nonsmall-cell lung cancer+. Annals of
Oncology 26,7:1415-1421.
Murgu, S.D. (2015). Diagnosing and staging lung cancer involving the
mediastinum. Chest 147,5:1401-1412.
Reck M and Paz-Ares L. (2015). Immunologic checkpoint blockade in lung cancer.
Seminars in oncology 42,3:402-417.
Prognosis, Survival & Risk Factors
5
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Beckett P, Edwards J, Fennell D, et al. (2015). Demographics, management and
survival of patients with malignant pleural mesothelioma in the National Lung
Cancer Audit in England and Wales. Lung Cancer 88,3:344-348.
Cardwell CR, Mc Menamin U, Hughes CM, et al. (2015). Statin use and survival from
lung cancer: a population-based cohort study. Cancer Epidemiology, Biomarkers &
Prevention 24,5:833-841.
Consonni D, Pierobon M, Gail MH, et al. (2015). Lung cancer prognosis before and
after recurrence in a population-based setting. Journal of the National Cancer
Institute 107,6:j059.
Deepak JA, Ng X, Feliciano J, et al. (2015). Pulmonologist involvement, stagespecific treatment, and survival in adults with non-small cell lung cancer and
chronic obstructive pulmonary disease. Annals of the American Thoracic Society
12,5:742-751.
Langer CJ, Hirsh V, Okamoto I, et al. (2015). Survival, quality-adjusted survival, and
other clinical end points in older advanced non-small-cell lung cancer patients
treated with albumin-bound paclitaxel. British journal of cancer 113,1:20-29.
Radiotherapy & Imaging
Adebahr S, Collette S, Shash E, et al. (2015). LungTech, an EORTC Phase II trial of
stereotactic body radiotherapy for centrally located lung tumours: a clinical
perspective. British Journal of Radiology 88,1051:20150036.
Berman AT, James SS and Rengan R. (2015). Proton Beam Therapy for Non-Small
Cell Lung Cancer: Current Clinical Evidence and Future Directions. Cancers
7,3:1178-1190.
Bezjak A, Temin S, Franklin G, et al. (2015). Definitive and Adjuvant Radiotherapy
in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical
Oncology Clinical Practice Guideline Endorsement of the American Society for
Radiation Oncology Evidence-Based Clinical Practice Guideline. Journal of
Clinical Oncology 33,18:2100-2105.
Boily G, Filion E, Rakovich G, et al. (2015). Stereotactic Ablative Radiation Therapy
for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and
Recommendations. Journal of Thoracic Oncology: Official Publication of the
International Association for the Study of Lung Cancer 10,6:872-882.
Casutt A, Bouchaab H, Beigelman-Aubry C, et al. (2015). Stereotactic body
radiotherapy with helical TomoTherapy for medically inoperable early stage
primary and second-primary non-small-cell lung neoplasm: 1-year outcome and
toxicity analysis. British Journal of Radiology 88,1049:20140687.
Feng W, Zhang Q, Fu XL, et al. (2015). The emerging outcome of postoperative
radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the
three-dimensional conformal radiotherapy technique and institutional standard
clinical target volume. BMC Cancer 15,348.
6
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Fontanarosa D, Witte M, Meijer G, et al. (2015). Probabilistic evaluation of target
dose deterioration in dose painting by numbers for stage II/III lung cancer.
Practical Radiation Oncology 5,4:e375-82.
Grootjans W, de Geus-Oei LF, Troost EG, et al. (2015). PET in the management of
locally advanced and metastatic NSCLC. Nature Reviews Clinical Oncology
12,7:395-407.
Hudson BJ, Crawford MB and Curtin JJ. (2015). Brain imaging in lung cancer
patients without symptoms of brain metastases: a national survey of current
practice in England. Clinical radiology 70,6:610-613.
James J, Swanson C, Lynch B, et al. (2015). Quantification of planning target
volume margin when using a robotic radiosurgery system to treat lung tumors
with spine tracking. Practical Radiation Oncology 5,4:e337-43.
Kepka L and Socha J. (2015). PET-CT use and the occurrence of elective nodal
failure in involved field radiotherapy for non-small cell lung cancer: A systematic
review. Radiotherapy & Oncology 115,2:151-156.
Pattenden HA, Leung M, Beddow E, et al. (2015). Test performance of PET-CT for
mediastinal lymph node staging of pulmonary carcinoid tumours. Thorax
70,4:379-381.
Rodrigues G, Choy H, Bradley J, et al. (2015). Adjuvant radiation therapy in locally
advanced non-small cell lung cancer: Executive summary of an American
Society for Radiation Oncology (ASTRO) evidence-based clinical practice
guideline. Practical Radiation Oncology 5,3:149-155.
Rodrigues G, Choy H, Bradley J, et al. (2015). Definitive radiation therapy in locally
advanced non-small cell lung cancer: Executive summary of an American
Society for Radiation Oncology (ASTRO) evidence-based clinical practice
guideline. Practical Radiation Oncology 5,3:141-148.
Siva S, Chesson B, Callahan JW, et al. (2015). Dosimetric Consequences of 3D
Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy.
Journal of Thoracic Oncology: Official Publication of the International Association for
the Study of Lung Cancer 10,7:1112-1115.
Siva S, Kirby K, Caine H, et al. (2015). Comparison of Single-fraction and Multifraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose
Positron Emission Tomography-staged Pulmonary Oligometastases. Clinical
Oncology (Royal College of Radiologists) 27,6:353-361.
Siva S, Thomas R, Callahan J, et al. (2015). High-resolution pulmonary ventilation
and perfusion PET/CT allows for functionally adapted intensity modulated
radiotherapy in lung cancer. Radiotherapy & Oncology 115,2:157-162.
Takahashi W, Nakajima M, Yamamoto N, et al. (2015). A prospective
nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset
of locally advanced non-small cell lung cancer (NSCLC). Cancer 121,8:1321-1327.
Supportive Care & Symptom Management
7
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Arnold DT, Hooper CE, Morley A, et al. (2015). The effect of chemotherapy on
health-related quality of life in mesothelioma: results from the SWAMP trial.
British journal of cancer 112,7:1183-1189.
Arrieta O, Vega-Gonzalez MT, Lopez-Macias D, et al. (2015). Randomized, openlabel trial evaluating the preventive effect of tetracycline on afatinib induced-skin
toxicities in non-small cell lung cancer patients. Lung Cancer 88,3:282-288.
Bade BC, Thomas DD, Scott JB, et al. (2015). Increasing physical activity and
exercise in lung cancer: reviewing safety, benefits, and application. Journal of
Thoracic Oncology: Official Publication of the International Association for the Study of
Lung Cancer 10,6:861-871.
Brady GC, Carding PN, Bhosle J, et al. (2015). Contemporary management of voice
and swallowing disorders in patients with advanced lung cancer. Current Opinion
in Otolaryngology & Head & Neck Surgery 23,3:191-196.
Brocken P, van der Heijden EH, Oud KT, et al. (2015). Distress in suspected lung
cancer patients following rapid and standard diagnostic programs: a prospective
observational study. Psycho-oncology 24,4:433-441.
Hendriksen E, Williams E, Sporn N, et al. (2015). Worried together: a qualitative
study of shared anxiety in patients with metastatic non-small cell lung cancer
and their family caregivers. Supportive Care in Cancer 23,4:1035-1041.
Kukec RR, Grabnar I, Vovk T, et al. (2015). Febrile neutropenia in chemotherapy
treated small-cell lung cancer patients. Radiology & Oncology 49,2:173-180.
LeBlanc TW, Samsa GP, Wolf SP, et al. (2015). Validation and real-world
assessment of the Functional Assessment of Anorexia-Cachexia Therapy
(FAACT) scale in patients with advanced non-small cell lung cancer and the
cancer anorexia-cachexia syndrome (CACS). Supportive Care in Cancer 23,8:23412347.
Molassiotis A, Charalambous A, Taylor P, et al. (2015). The effect of resistance
inspiratory muscle training in the management of breathlessness in patients with
thoracic malignancies: a feasibility randomised trial. Supportive Care in Cancer
23,6:1637-1645.
Salhi B, Haenebalcke C, Perez-Bogerd S, et al. (2015). Rehabilitation in patients
with radically treated respiratory cancer: A randomised controlled trial
comparing two training modalities. Lung Cancer 89,2:167-174.
Shen MJ, Coups EJ, Li Y, et al. (2015). The role of posttraumatic growth and timing
of quitting smoking as moderators of the relationship between stigma and
psychological distress among lung cancer survivors who are former smokers.
Psycho-oncology 24,6:683-690.
van den Hurk DG, Schellekens MP, Molema J, et al. (2015). Mindfulness-Based
Stress Reduction for lung cancer patients and their partners: Results of a mixed
methods pilot study. Palliative medicine 29,7:652-660.
Zaric B, Kovacevic T, Stojsic V, et al. (2015). Neodymium yttrium-aluminium-garnet
laser resection significantly improves quality of life in patients with malignant
central airway obstruction due to lung cancer. European Journal of Cancer Care
8
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
24,4:560-566.
Surgery
Bott MJ, Patel AP, Crabtree TD, et al. (2015). Role for Surgical Resection in the
Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer. Annals of
Thoracic Surgery 99,6:1921-1928.
Cao C, Chandrakumar D, Gupta S, et al. (2015). Could less be more?-A systematic
review and meta-analysis of sublobar resections versus lobectomy for non-small
cell lung cancer according to patient selection. Lung Cancer 89,2:121-132.
Hamaji M, Ali SO and Burt BM. (2015). A meta-analysis of resected metachronous
second non-small cell lung cancer. Annals of Thoracic Surgery 99,4:1470-1478.
Navani N, Nankivell M, Lawrence DR, et al. (2015). Lung cancer diagnosis and
staging with endobronchial ultrasound-guided transbronchial needle aspiration
compared with conventional approaches: an open-label, pragmatic, randomised
controlled trial. The Lancet Respiratory Medicine 3,4:282-289.
Samson P, Patel A, Garrett T, et al. (2015). Effects of Delayed Surgical Resection
on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung
Cancer. Annals of Thoracic Surgery 99,6:1906-1913.
Vilmann P, Frost Clementsen P, Colella S, et al. (2015). Combined endobronchial
and esophageal endosonography for the diagnosis and staging of lung cancer:
European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in
cooperation with the European Respiratory Society (ERS) and the European
Society of Thoracic Surgeons (ESTS). European Journal of Cardio-Thoracic Surgery
48,1:1-15.
Tobacco & Smoking
NICE. Quality Standard 92: Smoking: harm reduction. July 2015
Jimenez-Ruiz CA, Andreas S, Lewis KE, et al. (2015). Statement on smoking
cessation in COPD and other pulmonary diseases and in smokers with
comorbidities who find it difficult to quit. European Respiratory Journal 46,1:61-79.
Please note that the journal articles you are accessing are subject to the terms and conditions
imposed by the publisher, so there will be a limit on the number of articles an individual may
download or print from a single issue of a journal. You can consult your local NHSGGC library with
any queries.
9
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin: OVID MEDLINE, SIGN, NICE, Healthcare Improvement Scotland
1
0
Lung Cancer, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network